Testing effectiveness (Phase 2)WithdrawnNCT03328936
What this trial is testing
Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant
Who this might be right for
Hematopoietic Cell Transplantation RecipientRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Ohio State University Comprehensive Cancer Center